BCLI חוב כולל להון BrainStorm Cell Therapeutics

Brainstorm Cell (BCLI) bases its development of neurodegeneration treatments on patented biomaterial processing methods and strict FDA standards. The company retains its scientific staff through a stock option system, which prevents the loss of key experts. The price history on the total debt-to-equity chart is recorded at 0.00. The business is centered on the creation of the NurOwn cell platform, awaiting approval of its ALS therapy to enter the orphan drug market.

For Brainstorm Cell (BCLI), which is scaling the NurOwn platform in neurology, managing leverage is critical when financing costly clinical trials. By analyzing the leverage ratio—the relationship of total debt to equity—an investor assesses the proportion of borrowed funds within the liability structure relative to equity, which determines the company's degree of financial autonomy and its resilience to bankruptcy risks during long-term expansion.